Exato Technologies

Q4 FY27 Earnings Call Analysis

IT - Services

Full Stock Analysis
margin: Category 1orderbook: Yesfundraise: No informationcapex: Yesrevenue: Category 2
💰

fundraise

Any current/future new fundraising through debt or equity?

- The transcript does not explicitly mention any current or planned new fundraising through debt or equity. - The company recently got listed (around 1-1.5 months ago as of February 2026). - There is mention of funding part for product and IP development as a part of the listing. - No direct comments about new debt or equity fundraising rounds were made during the call. - The focus appears to be on organic and inorganic growth through partnerships, acquisitions, and investments in R&D, not new fundraising. - Investors have shown confidence by increasing stakes, implying no immediate need for fresh equity. - Overall, no current or upcoming fundraising via debt or equity is indicated in the provided pages.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- Building a global office based out of Noida, which will be a large 24x7 facility covering US, Australia, Singapore, and UK business development as well as network operations center and support center. - Investment in R&D with plans to bring in a chief AI officer with significant experience. - Launching a talent residency program to attract good talent with infrastructure, guidance, and customer access. - Registering a subsidiary in Australia to aid international expansion. - Exploring inorganic growth through acquisitions of three companies, which would add diversification and market access in Middle East, Africa, and the US. - Infrastructure division development to support license deployment and cloud infrastructure, aiming for sustained quarter-on-quarter growth. - Build a scalable global sales engine with SDR and BDR teams across geographies for better international market penetration.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- The company expects significant growth potential with ambitions to become a very sizable firm in the next five years (Page 24). - Revenue growth for Q4 is projected at 25-30%, with PAT growth expected in the range of 50-60% compared to last year (Page 19). - Large deals of 100+ Cr are expected annually, contributing to sustained revenue growth with ARR rising from 20 Cr three years ago to a projected 100-110 Cr this year (Page 19, 16). - Expansion into international markets like US, Australia, UK, and Singapore is expected to drive better revenue and profitability (Pages 24, 13, 10). - Increasing focus on cloud license subscriptions, analytics, AI, and IP/product development aims to aid recurring revenue and profitability growth (Pages 24, 19, 11). - Growth is also targeted through large contracts in healthcare, BFSI, IT-ITES verticals and new leadership driving aggressive global market development (Pages 24, 11, 10).
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Revenue growth for Q4 FY26 is expected to be around 25-30% compared to last year, Q4. - Profit After Tax (PAT) growth for Q4 FY26 is projected at 50-60%. - Operating profit is expected to increase with continued delivery of large contracts and international expansion. - Sustainable operating profit margin target is hinted to improve beyond current 13-19%, with potential to reach higher levels as international markets mature. - Significant profitability improvement is anticipated as international operations scale, especially with new leadership focused on global market development. - The company aims for big growth ambitions over the next five years, aspiring to become a sizable company globally. - Revenue and PAT growth are expected to be stronger starting FY27 with new IP services generating revenue from Q3 FY27 onwards. - Continued focus on customer experience, AI, analytics, and global expansion is expected to drive future profitability.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- Total current order book is approximately ₹348 crore. - Of this, around ₹210-220 crore is from the healthcare segment. - IKS Health contributes about ₹130 crore to the order book. - Another major healthcare client, BLS, has an order book of ₹95 crore. - Additional healthcare contracts include: - A London-based customer: ₹60-65 crore - An airline BPO: ₹55-60 crore - A contract worth ₹21-25 crore with another customer from India. - Order book is growing at 30-40% year-on-year with expected increases driven by international expansion. - The company expects significant topping-off in 5-year contracts leading to spikes in profitability. - Plans include expanding international regions and diversifying product lines to boost order book, revenue, and profitability by at least 30-40%.